Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
Status:
Not yet recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide medication for opioid use disorder (MOUD) with
buprenorphine and naloxone, or bup/nx, pre-exposure prophylaxis (PrEP) for HIV prevention,
and/or hepatitis C treatment for persons who inject opioids accessing syringe services
programs (SSPs), as part of a comprehensive harm reduction program, and assess the
acceptability and feasibility of using telemedicine to implement the program.
The initial visit will be conducted in person or remotely via telemedicine given COVID-19
protocols at the SSP site in Greensboro, North Carolina (NC); follow-up visits will be
conducted via telemedicine.
Phase:
Phase 4
Details
Lead Sponsor:
Duke University
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Naloxone